ERα and PR, along with human epidermal growth factor receptor 2 (HER2), are used to classify phenotypes in breast cancers and to predict response to specific therapies (Cadoo, Fornier & Morris, 2013; Kittler et al., 2013). Here, PGR is linked to breast carcinoma.